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Acute asthma remains an important medical emergency, the most frequent cause of acute 
admissions in children and a major source of morbidity for adults with asthma. In all ages with 
asthma the presence of exacerbations is an important defining characteristic of asthma severity. In 
this review we will assess the epidemiology of acute asthma, the triggers of acute exacerbations 
and the mechanisms that underlie these exacerbations. We will also assess current treatments 
that prevent exacerbations, with an emphasis on the role of type 2 airway inflammation in the 
context of acute exacerbations and the novel treatments that effectively target this. Finally we will 
review current management strategies of the exacerbations themselves. 
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Acute exacerbations of asthma remain a serious treatment challenge. They are a frequent 
cause of hospital admission or emergency room (ER) presentation, especially in children and 
according to the World Health Organisation, asthma was responsible for 383,000 deaths in 2015. 
Exacerbations are now considered to be key in defining the severity of the disease and their 
prevention is an important metric to measure success of asthma treatments (1). Definitions of 
acute asthma or exacerbations have varied over the years, and a more precise definition was 
required to standardize outcomes in clinical trials and clinical medicine. As a result, the ATS/ERS 
convened a task force to define exacerbations as well as asthma control (2). Consequently, a 
severe exacerbation was defined as; the use of corticosteroids for at least 3 days or a 
hospitalisation or ER visit because of asthma requiring corticosteroids. Moderate exacerbations 
were defined as an event that required a change in treatment to prevent it from becoming severe 
and not severe enough to warrant oral corticosteroids (OCS). 
The interventions available for use in the setting of acute asthma are relatively limited, and 
the management of asthma exacerbations varies depending on severity and the treatment setting. 
Since the 1960s treatment for acute asthma has focused on the use of systemic corticosteroids 
and selective beta-2 agonists, and unfortunately there have been few new treatments trialled and 
little added of particular efficacy to the armamentarium of acute management with the exception 
of supportive measures. The treatment of asthma exacerbation currently begins with asthma self-
management in the outpatient setting. As the severity of the presentation escalates, so do 
treatment regimens and the support required. Here we review the mechanisms that underpin 
acute asthma and its management.  
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What causes acute exacerbations  
Epidemiology 
Malcolm Sears succinctly summarized the data that describes the epidemiology of acute 
asthma, emphasizing the importance of age, sex and seasonality (Figure 1)(3). Acute asthma 
remains predominantly a disease of early childhood, with more boys affected before puberty, and 
then a switch occurs where females are more likely to suffer with acute asthma that persists 
throughout life. There is a peak of events when children return to school in autumn, with younger 
children and adults experiencing less pronounced increases following this and a smaller peak that 
occurs in those over 50 years in midwinter, with both of these peaks associated with the presence 
of virus infections (3). 
These events seem to hold true across the developed world and are well illustrated by 
Australian data (4). The problem is greatest in childhood, with children being hospitalized at a 
prevalence of 495/100,000, compared to adults at 92/100,000. Deaths from asthma though were 
rare in 2016 with only 455 and two thirds of these were in those aged greater than 75 years. This 
epidemiological data also demonstrates how much asthma is also a disease of the social 
environment. In Australia, despite universal public healthcare the prevalence of acute asthma was 
higher in populations with a lower socioeconomic background, was two-fold greater amongst 
indigenous communities and higher in adults living in remote areas (4). Outcomes of studies of the 
relationships between asthma incidence and lower socioeconomic status (SES) have varied from 
no relationship (5) to increased risk (6). In general while asthma tends to be a disease of the 
developed world, explained in part through the hygiene hypothesis, when present, poverty is 
nearly always associated with worse outcomes (7). Lower SES has consistently been shown to be 
an independent risk for poor asthma control and exacerbations (8, 9) even when complicated by 
ethnicity (10). In developing nations, poverty or low SES is similarly associated with poor asthma 
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outcomes (11). The reasons for this are likely to be complex, including poor nutrition, access to 
health care, affordability of medicine, and exposure to cigarette smoke and/or pollution (7). While 
easy to dismiss as a problem to be solved by government and changes in social policy, well 
conducted, patient-centred interventions that focus on self-management can successfully deliver 
improved outcomes including reducing exacerbations (12). 
 
Triggers for acute asthma 
The seasonal variation in asthma exacerbations especially in children has already been 
described, particularly the marked increase that accompanies the return to school in Autumn. This 
has been linked strongly with the presence of rhinovirus (RV) infection and lack of preventer use in 
Canadian children aged 5-15 years (13). Less intense peaks have also been seen in mid-winter in 
older adults and patients with chronic obstructive pulmonary disease and associated with 
influenza (14). While other factors contribute to this seasonal variation in acute asthma, in school-
age children, the community prevalence of RV is the strongest predictor (15). Associations 
between respiratory infections and acute asthma has been recognised for centuries, as described 
in 1864 by Henry Salter (himself an asthmatic) “the most prominent and frequent of all exciting 
causes is what is commonly called taking cold … The asthma consequent on cold on the chest 
(bronchitis) is of a most painful and distressing kind; unlike that produced by cold directly, it often 
lasts for days”. The ability to identify viruses by polymerase chain reactions (PCR), demonstrated 
that they were associated with 80-85% of asthma exacerbations in children (16) and the majority 
in adults (17), with RV the most common. While true to Salter’s description exacerbations 
associated with viral infections have also been shown to cause more severe disease (18). 
Recently it has been shown that certain RV strains are more closely linked to acute asthma. 
In children the newly identified RV-C strain was detected in 59.4% and was associated with more 
severe disease (19). In childhood, RV-C strains seem particularly capable of causing exacerbations, 
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while infections with RV-A strains require a higher viral titre to trigger an exacerbation, whereas 
RV-B strains seem relatively benign (20). RV-C binds to epithelial cells via the cadherin-related 
family member 3 protein, with a missense single nucleotide polymorphism (rs6967330, C529Y) 
linked to greater cell-surface expression (21). This mutation has also been linked to childhood 
severe asthma exacerbations (22), and recently this enhanced risk was found to be due to RV-C 
associated exacerbations in two separate birth cohorts (23). While this strong association has 
been seen in children with acute asthma and RV-C, it does not seem to hold true for adults where 
RV-A dominates and RV-C was rarely identified in Australian (24) and US cohorts (25). 
 Environmental factors also influence asthma exacerbations. A Canadian study showed that 
after adjusting for season and air pollution a doubling in grass pollen levels and fungal spore 
counts increased asthma admissions (26). A US study also showed a potential relationship 
between mould spore levels and asthma deaths (27), and a metanalysis linked outdoor pollen 
exposure to acute asthma events (28). More recently an Australian study demonstrated three 
separate peaks of asthma admissions, the first two related to virus infection, but the third in late 
spring correlated with high grass pollen counts and high humidity, implicating thunderstorms as a 
trigger (29). Acute thunderstorm asthma events are extreme examples of this phenomena, where 
high pollen counts combine with atmospheric conditions that induce severe acute asthma 
epidemics (30, 31), associated with intense type 2 airway inflammation (32)(Figure 1). 
 
Exacerbation prone asthma phenotype 
Within populations the risk of asthma exacerbations is not equal. In children a history of 
previous severe exacerbations appears to be the strongest predictor along with poor asthma 
symptom control and disease severity (33-35). This risk though appears to vary by season, with 
exacerbations occurring in autumn and winter (usually viral) predicted by a history of previous 
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exacerbations, and those in spring and summer by dose of inhaled corticosteroids (ICS) required 
for control (36). This suggests that events triggered by allergy may be better controlled by regular 
use of ICS. 
In adults, analysis of three clinical trials of greater than 7,000 subjects with asthma who 
had their treatment with ICS/long acting beta-agonist (LABA) therapy optimized, exacerbations 
were predicted by disease severity, asthma symptom control and a history of smoking (37). Unlike 
in childhood, in adults, comorbid disease is also an important additional factor. This has been 
consistently seen with chronic rhinosinusitis, body mass index, and psychological dysfunction (38, 
39). In adults with severe asthma the complexity of this situation needs to be appreciated if 
effective strategies are to be designed to prevent exacerbations. Using registry data McDonald et 
al., demonstrated that 24 individual treatable traits could be identified in the domains of; 
pulmonary, extrapulmonary and behavioural factors that were over represented in those with 
severe asthma and were related to risk of exacerbation (40). In the context of severe asthma a 
single approach that only focuses on asthma disease control then is unlikely to be sufficient to 
improve patient outcomes. 
  
Poor asthma control and type 2 airway inflammation in acute asthma 
One key independent factor that emerges as an ongoing risk for exacerbations and 
provides insight into the pathophysiology of acute asthma is the presence of refractory type 2 
airway inflammation. Type 2 inflammation is characterized by the release of the cytokines 
interleukin (IL)-5, IL-4 and IL-13 produced by T-helper type-2 (Th2) cells and innate lymphoid cells 
of type 2 (ILC2 cells) and is associated with airway eosinophilia and elevated levels of exhaled 
nitric oxide.  
 Assessing subjects with both severe asthma as well as mild to moderate disease; severity 
and asthma symptom control independently predicted exacerbation risk, but so too did sputum 
eosinophilia or elevated exhaled nitric oxide (41). While adult onset asthma is often not associated 
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with atopy, a large number, especially those with more severe disease have evidence of type 2 
immune activation, with elevated sputum eosinophils and increased levels of exhaled nitric oxide 
(42). More recently blood eosinophils have been identified as a good predictor of airway 
eosinophils (43). In population samples of adults, elevated blood eosinophils are associated with 
increased risk of exacerbations. In 2,392 subjects with asthma, a blood eosinophil count of >0.4 
x109/ml independently predicted exacerbation risk with an odds ratio of 1.31 (95%CI 1.07 to 1.6) 
(44). This remained an independent predictor for exacerbations, even in those with poor asthma 
symptom control (45), and showed the strongest association with the most severe exacerbations 
that result in hospital admission (odds ratio; 5.14, 95%CI, 1.76 to 14.99) (46). Combining elevated 
blood eosinophils together with exhaled nitric oxide may further define those at greatest risk of 
future asthma exacerbations (47). The presence of active type 2 airway inflammation and its 
measurement with biomarkers, such as blood eosinophils and exhaled nitric oxide provides a clear 
indication of risk for future exacerbations. 
Non-type 2 airway inflammation in acute asthma 
While the role of type 2 airway inflammation in acute asthma is becoming much clearer, 
other immune processes are likely to also be important and future treatments will likely rely upon 
a clearer understanding of these (48). Acute exacerbations, especially those associated with virus 
infection have been shown to be associated with neutrophilic inflammation (49), though this may 
differ in children where there is more evidence of eosinophilic inflammation (50). Dysregulation of 
innate immune responses, including activation of inflammasome pathways and airway neutrophila 
have been seen to be distinct in  asthma with non-type 2 inflammation (51, 52), with  recent 
mechanistic and clinical studies implicating non-type 2 airway inflammatory mechanisms play a 
key role in exacerbations, with microRNAs and inflammasomes more likely involved in virus 




Management of exacerbations  
Controlling type 2 airway inflammation 
Control of type 2 airway inflammation is critical in preventing exacerbations (Table 1). 
Treatment with ICS remains the cornerstone strategy for the majority with asthma and is effective 
in most at reducing the risk of exacerbations, including the risk of death (55-57). Using either OCS 
or ICS, adjusted to suppress airway eosinophilia in asthma has been shown to effectively reduce 
the risk of exacerbations (58, 59). More recently biologic treatments that target specific aspects of 
type 2 immune responses in those with severe asthma and ICS refractory type 2 airway 
inflammation have been shown to reduce asthma exacerbations. Treatment of patients with 
severe allergic asthma with Omalizumab, a monoclonal antibody to IgE, reduces exacerbations in 
those with severe disease despite optimal doses of ICS/long acting beta-agonist (60). In subjects 
with severe asthma and refractory eosinophilia, monoclonal antibody therapy against IL-5 reduced 
exacerbation frequency by approximately half (61). While treatment with Dupilumab, a 
monoclonal therapy against IL-4 and IL-13, similarly reduced asthma exacerbations though only in 
those with persistent type 2 airway inflammation, as measured by either increased blood 
eosinophils or exhaled nitric oxide, despite treatment with ICS (62, 63). 
 
Adjusting ICS/OCS  
Control of type 2 airway inflammation prevents exacerbations, but also improves 
outcomes during an exacerbation. Treatment with systemic steroids, including 1-6 days of 
prednisone or dexamethasone, effectively reduced relapse rates in acute asthma in children (64). 
Similarly, in adults, systemic steroids reduced acute relapse rates, though the course of 
prednisone needed to be at least 7-10 days in duration, with shorter courses being ineffective 
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(65). Treatment with ICS cannot be used in place of OCS (66), but may prevent the need to use 
OCS in acute asthma. Quon et al., showed that doubling the maintenance dose of ICS at the start 
of an exacerbation was insufficient to prevent the use of OCS (67). More recently, however, 
Oborne et al., assessed whether a quadruple dose of ICS could prevent exacerbations needing OCS 
(68). Although they failed to reach their primary outcome, possibly because their platform event 
filler-triggered action plan provided a delayed response, those who did increase their ICS used less 
OCS.  
 A more flexible approach that adjusted ICS dose in response to symptoms has been shown 
to be more successful. Formoterol/budesonide combinations have shown utility in the setting of 
mild asthma exacerbations and loss of asthma control when used as maintenance and reliever 
therapy (69). The formoterol component in Symbicort has a rapid onset of action of 1-3 minutes 
and also a prolonged duration of action (70). The short onset of action is particular to formoterol 
containing inhalers, and allows it to be used as reliever therapy. This has a role in the setting of 
mild asthma exacerbations, where, instead of typical short acting bronchodilators, 
formoterol/budesonide combination inhalers lead to symptomatic bronchodilation along with the 
administration of extra ICS. Ideally, this extra ICS may be sufficient to target steroid-responsive 
inflammation that may be at the heart of the current exacerbation. As a result, adjustable dosing 
of budesonide formoterol is linked with better exacerbation control long-term (71). More recently 
this approach was used to show that as required use of Formoterol/budesonide, in those with 
mild intermittent disease also effectively reduced exacerbations and the need for OCS (72, 73). 
Definitive treatment in the setting of severe exacerbations currently involves therapy with 
OCS. Their use is associated with reduced recurrent asthma exacerbations, and emergency 
department and hospital admissions (74). Given that exacerbations are thought to often involve 
eosinophilic inflammation beyond what is typically managed with maintenance therapy in the 
patient’s day-to-day life, systemic corticosteroids effectively target this inflammation. They have 
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been shown to induce apoptosis in eosinophils, reduce mucus hypersecretion in the airways and 
prevent the recruitment of eosinophils. All of this contributes to their importance as a major 
therapy in the treatment of acute asthma exacerbations (75).  
 
Self-management 
The Global Strategy for Asthma Management and Prevention (GINA), along with most 
international respiratory societies, recommend self-management strategies to reduce the impact 
of acute exacerbations in all groups (1). This involves patient education and the provision of an 
individualised written asthma action plan. An action plan should include a description of regular 
maintenance therapy, and instructions for the escalation of therapy depending on either a 
worsening of symptoms or a change in peak flow monitoring (for examples see 
https://www.nationalasthma.org.au/health-professionals/asthma-action-plans/asthma-action-
plan-library). Action plans that include instructions using 2-4 action points and the use of both ICS 




Since the advent of metered dose inhalers for the treatment of bronchoconstriction, beta-
adrenergic bronchodilators have formed the mainstay of treatment of acute exacerbations. In the 
outpatient setting, patients are instructed to increase their use of short-acting bronchodilators in 
conjunction with their symptoms. Given their potential to mask symptoms and delay seeking of 
medical attention, it is important to adequately educate patients on the need to pursue further 
treatment, typically with increasing doses of corticosteroids (77). While important during the 
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acute management of the symptoms of an exacerbation, typically bronchodilators do not treat the 
underlying inflammation that underpin the exacerbation, particularly eosinophilic inflammation. 
Because of their short onset of action, short-acting bronchodilators are used in this setting, 
most commonly beta-2-agonists but also short-acting anti-muscarinics. Both act on airway smooth 
muscle to promote bronchodilation. This is mediated by beta-adrenergic stimulation of smooth 
muscle to enact bronchodilation or cholinergic antagonism to relieve bronchial constriction that is 
under parasympathetic activity (78, 79). Treatment is primarily symptomatic, as bronchodilation 
does not target the underlying inflammation that drives the exacerbation.   
Magnesium 
Typically, the use of magnesium sulfate is limited to those situations where asthma 
exacerbation is refractory to treatment with bronchodilators and steroids alone. Parenteral 
administration is used as it has greater bioavailability compared to oral magnesium (80). A 
Cochrane review demonstrated reduced hospital admissions and a small improvement in lung 
function with the use of magnesium sulfate in the emergency department (81). A review by Ling et 
al., did not demonstrate any reduction in hospital admissions with the use of nebulized 
magnesium, and thus there is not a clear benefit of nebulised administration at this point (82). 
Another Cochrane review assessed comparisons between the administration of inhaled 
magnesium sulfate and b2-agonist with b2-agonist alone also did not show any improvement in 
lung function or hospital admission rate (83). These findings seem to be equivalent in children 
(84). 
Treating infection and non-type 2 inflammation 
Infection plays a crucial role in triggering acute asthma. Experimental studies show 
impaired innate immune responses to virus infections in asthma (85), and that infections induce 
microRNAs and inflammasome activation that suppress responses to corticosteroids(53, 54). 
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Investigators sought to determine if treatment at the time of a cold with nebulised interferon 
would reduce exacerbation severity in those with a history of virus-induced acute asthma. 
Treatment though did not improve the severity of acute asthma symptoms overall, except in those 
with pre-existing poor control and more severe disease (86). In contrast to acute exacerbations of 
COPD, there is no evidence that antibiotics improve outcomes in acute asthma (87). This is likely 
since the majority of exacerbations are associated with viral infections. Macrolide antibiotics have 
been used to reduce the frequency of exacerbations of asthma and other airways disease and are 
proposed to have anti-inflammatory effects. In a trial of 278 adults with asthma treatment with 
the ketolide Telithromycin was shown to improve asthma symptom scores (88), but it was later 
withdrawn due to toxicity. A similar trial attempted to assess add on azithromycin to see if this 
would improve asthma symptoms acutely, the trial failed to demonstrate a difference, though the 
investigators had to exclude 10 subjects for everyone randomised as they had already received 
antibiotics (89). Azithromycin has also been used in preschool children (1-3 years) presenting with 
acute wheezing illnesses, but has had mixed results, with one trial demonstrating a reduction in 
length of symptoms (90), and another failing to show improvement in clinical outcomes (91). 
Antimicrobials, instead, should be reserved for those cases where there is clinical suspicion for 
bacterial infection that would require treatment in conjunction with treatment of the asthma 
exacerbation (1).  
In terms of preventing exacerbations targeting non-type 2 immune mechanisms there have 
been mixed results (Table 2). In adults with moderate to severe asthma regular azithromycin 
reduced exacerbation risk in those with and without eosinophilic airway inflammation in an 
Australian study (92), but not in a European study (93). Tiotropium a long acting anticholinergic 
bronchodilator has also been shown to reduce exacerbation risk in those on ICS/LABA, in adults 
and children with asthma, while long acting beta agonists alone have not (94). Omalizumab as 
discussed reduces exacerbations, but recent evidence suggests part of its effect may be by 
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improving antiviral immune responses (95).  However monoclonal antibodies that targeted TH-17 
(96) and tumour necrosis factor-alpha	(97)	failed	to	reduce	exacerbations.  
 
Conclusions 
Treatment of asthma exacerbations using the therapies described is successful for a large 
proportion of patients. Indeed, as a result, over the course of the last 100 years, the mortality rate 
from asthma exacerbations has declined considerably. This has largely been due to the recognition 
of corticosteroids as a cornerstone of treatment of asthma exacerbations. Despite these 
improvements, there remains a significant ongoing mortality rate due to asthma that appears to 
have reached a plateau in the developed world. With the advent of precision medicine and 
targeted therapies, there have been many new insights into the management of chronic disease in 
asthma, however, this has not yet been seen with exacerbations. We remain hopeful that further 
advances will see further decline in mortality due to asthma – whether this be due to advances in 




Table 1 Preventing acute asthma 
Therapeutic Mechanism of 
action 
Clinical effect Asthma phenotype References 
ICS Effective in control 
of type 2 airway 
inflammation, 











in all with asthma, 
effect clearly 
greatest in those 
with Type 2 
immune activation. 
(56, 64-68, 74, 
75, 98, 99) 
Omalizumab Monoclonal 
antibody against 













Moderate to severe 
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moderate to severe 
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stage not limited to 
an inflammatory 
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on 1 RCT). 
(102) 
Tiotropium Long acting 
antimuscarinic 
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may be effective in 
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Class Example Effect References 
SABA/SAMA 1. Inhaled 
bronchodilator 
Salbutamol MDI 
(100mcg/puff) 2-4 puffs q1h 
PRN 
Atrovent MDI (17mcg/puff) 2 
puffs q4h PRN 
(up to q20min in ED acutely) 
Symptomatic relief: Beta-2-
agonist leading to smooth 
muscle cell relaxation 











dry powder device 
(200/6mcg) 1-2 puffs as 
needed (max. 8/day) 
Ciclesonide (160) 4 puffs TID 
Treat steroid-responsive 
inflammation in mild to 
moderate asthma 
exacerbations. Potentially 
avoids the necessity of 
systemic corticosteroids. 
(68, 69, 72, 73) 
Oral steroids 2. Systemic 
corticosteroid 
Adults Prednisone 37.5 to 
50mg daily for 7 days 
Children >6 years give 
prednisone 1 mg/kg 





inflammation in asthma 
exacerbation. Reduces 
relapse and hospitalization 
rates. 
(64, 65, 74) 
Magnesium 3. Elemental 
magnesium 






Table  2: Summary of treatment modalities for asthma exacerbation. In the acute setting, the use 
of Class 1 medications for symptom relief is standard, in addition to Class 2 to target inflammation 
at the heart of an acute exacerbation and prevent relapse. Class 3 medications are typically used 
in refractory situations, or where there is clinical need for treatment of comorbidities or ongoing 
supportive management. SABA (Short acting bronchodilator), SAMA (short acting antimuscarinic). 






Legend Figure 1 
Figure 1: Acute exacerbations of asthma follow a pattern of seasonal variation. A number of peaks 
of acute asthma activity occurs. There is a marked increase that accompanies the return to school 
in Autumn. This has been linked strongly with the presence of rhinovirus (RV) infection and lack of 
preventer use in school children with asthma. A less intense peak has also been seen in mid-winter 
in older adults and patients with chronic obstructive pulmonary disease and associated with 
influenza and other winter related respiratory tract infections. Exposure to allergens however is 
also important. After adjusting for season and air pollution a doubling in grass pollen levels and 
fungal spore counts is also associated with increased asthma admissions. This is associated with a 
third peak in late spring correlated with high grass pollen counts and high humidity, seen through 
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